Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(165 products)
- Bcr-Abl(117 products)
- EGFR(561 products)
- FAK(72 products)
- FLT(89 products)
- Fibroblast Growth Factor Receptor (FGFR)(177 products)
- JAK(243 products)
- PDGFR(127 products)
- RAAS(86 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(51 products)
- VDA(2 products)
- VEGFR(239 products)
Show 6 more subcategories
Found 2254 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-48
EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.Color and Shape:SolidBMS-066
CAS:BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.Formula:C19H21N7O2Purity:98%Color and Shape:SolidMolecular weight:379.42FGFR4-IN-10
FGFR4-IN-10 (compound 5a) is a potent, selective FGFR4 inhibitor with IC50 of 70.7 nM, sparing FGFR1-3.Formula:C20H19F3N6O3Color and Shape:SolidMolecular weight:448.4TYK2 ligand 2
CAS:TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.Formula:C24H20FN7O4Color and Shape:SolidMolecular weight:489.458BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formula:C28H24FN5O2Color and Shape:SolidMolecular weight:481.52FGFR-IN-6
CAS:FGFR-IN-6 (Compound 5) is an FGFR inhibitor.Formula:C23H22N6O3Color and Shape:SolidMolecular weight:430.46Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formula:C10H8N2OColor and Shape:SolidMolecular weight:172.183iBFAR2
CAS:iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.
Formula:C19H15F3N2O2Color and Shape:SolidMolecular weight:360.33CMV-423
CAS:CMV-423 is an antiviral agent exhibiting effective in vitro activity against beta-herpesviruses, including Human Cytomegalovirus (HCMV), Human Herpesvirus 6 (HHV-6), and Human Herpesvirus 7 (HHV-7). It is utilized in antiviral research.Formula:C14H14ClN3OColor and Shape:SolidMolecular weight:275.73Andamertinib
CAS:Andamertinib is an EGFR inhibitor with antitumor activity.Formula:C31H36N8O3Color and Shape:SolidMolecular weight:568.669EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formula:C26H28ClN3O4Color and Shape:SolidMolecular weight:481.97EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formula:C27H25ClN2O4Color and Shape:SolidMolecular weight:476.951VEGFR-2-IN-10
VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.Formula:C20H21N3O2Color and Shape:SolidMolecular weight:335.4MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formula:C28H44N8O5Purity:98%Color and Shape:SolidMolecular weight:572.70Lomonitinib
CAS:Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.
Formula:C27H24N4O2Color and Shape:SolidMolecular weight:436.505EGFR-IN-146
CAS:EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Formula:C20H16N4Color and Shape:SolidMolecular weight:312.368MTX-216
CAS:MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Formula:C22H14Cl2FN5O2SColor and Shape:SolidMolecular weight:502.348FGFR4-IN-4
CAS:FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.Formula:C28H32Cl2N6O5Purity:98%Color and Shape:SolidMolecular weight:603.5BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formula:C31H24Cl2N4O4Color and Shape:SolidMolecular weight:587.45JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formula:C21H25ClN8OColor and Shape:SolidMolecular weight:440.93
